Hepatic Stellate Cell Transdifferentiation Involves Genome-wide Remodeling of the DNA Methylation Landscape

Overview

Journal J Hepatol

Publisher Elsevier

Specialty Gastroenterology

Date 2015 Dec 4

PMID 26632634

Citations 62

Authors

Agata Page

Pier Paoli

Eva Moran Salvador

Steve White

Jeremy French

Jelena Mann

Affiliations

Soon will be listed here.

Abstract

Background & Aims: DNA methylation (5-mC) is an epigenetic mark that is an established regulator of transcriptional repression with an important role in liver fibrosis. Currently, there is very little knowledge available as to how DNA methylation controls the phenotype of hepatic stellate cell (HSC), the key cell type responsible for onset and progression of liver fibrosis. Moreover, recently discovered DNA hydroxymethylation (5-hmC) is involved in transcriptional activation and its patterns are often altered in human diseases. The aim of this study is to investigate the role of DNA methylation/hydroxymethylation in liver fibrosis.

Methods: Levels of 5-mC and 5-hmC were assessed by slot blot in a range of animal liver fibrosis models and human liver diseases. Expression levels of TET and DNMT enzymes were measured by qRT-PCR and Western blotting. Reduced representation bisulfite sequencing (RRBS) method was used to examine 5-mC and 5-hmC patterns in quiescent and in vivo activated rat HSC.

Results: We demonstrate global alteration in 5-mC and 5-hmC and their regulatory enzymes that accompany liver fibrosis and HSC transdifferentiation. Using RRBS, we show exact genomic positions of changed methylation patterns in quiescent and in vivo activated rat HSC. In addition, we demonstrate that reduction in DNMT3a expression leads to attenuation of pro-fibrogenic phenotype in activated HSC.

Conclusions: Our data suggest that DNA 5-mC/5-hmC is a crucial step in HSC activation and therefore fibrogenesis. Changes in DNA methylation during HSC activation may bring new insights into the molecular events underpinning fibrogenesis and may provide biomarkers for disease progression as well as potential new drug targets.

Citing Articles

Association Between Active DNA Demethylation and Liver Fibrosis in Individuals with Metabolic-Associated Steatotic Liver Disease (MASLD).

Barchetta I, Zampieri M, Cimini F, Dule S, Sentinelli F, Passarella G Int J Mol Sci. 2025; 26(3).

PMID: 39941038 PMC: 11818491. DOI: 10.3390/ijms26031271.

Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells.

Akkiz H, Gieseler R, Canbay A Int J Mol Sci. 2024; 25(14).

PMID: 39063116 PMC: 11277292. DOI: 10.3390/ijms25147873.

Role of Folate in Liver Diseases.

Yang M, Wang D, Wang X, Mei J, Gong Q Nutrients. 2024; 16(12).

PMID: 38931227 PMC: 11206401. DOI: 10.3390/nu16121872.

Exportin 4 DNA promoter methylation in liver fibrosis.

Pan Z, Bayoumi A, Metwally M, George J, Eslam M PLoS One. 2024; 19(5):e0302786.

PMID: 38722973 PMC: 11081319. DOI: 10.1371/journal.pone.0302786.

Survivin inhibition ameliorates liver fibrosis by inducing hepatic stellate cell senescence and depleting hepatic macrophage population.

Sharma S, Ghufran S, Aftab M, Bihari C, Ghose S, Biswas S J Cell Commun Signal. 2024; 18(1):e12015.

PMID: 38545255 PMC: 10964939. DOI: 10.1002/ccs3.12015.

References

Montosi G, Garuti C, Iannone A, Pietrangelo A . Spatial and temporal dynamics of hepatic stellate cell activation during oxidant-stress-induced fibrogenesis. Am J Pathol. 1998; 152(5):1319-26. PMC: 1858581. View

Mann J, Chu D, Maxwell A, Oakley F, Zhu N, Tsukamoto H . MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology. 2009; 138(2):705-14, 714.e1-4. PMC: 2819585. DOI: 10.1053/j.gastro.2009.10.002. View

Gotze S, Schumacher E, Kordes C, Haussinger D . Epigenetic Changes during Hepatic Stellate Cell Activation. PLoS One. 2015; 10(6):e0128745. PMC: 4466775. DOI: 10.1371/journal.pone.0128745. View

Zeybel M, Hardy T, Robinson S, Fox C, Anstee Q, Ness T . Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease. Clin Epigenetics. 2015; 7:25. PMC: 4391139. DOI: 10.1186/s13148-015-0056-6. View

Mann J, Oakley F, Akiboye F, Elsharkawy A, Thorne A, Mann D . Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ. 2006; 14(2):275-85. DOI: 10.1038/sj.cdd.4401979. View

Komatsu Y, Waku T, Iwasaki N, Ono W, Yamaguchi C, Yanagisawa J . Global analysis of DNA methylation in early-stage liver fibrosis. BMC Med Genomics. 2012; 5:5. PMC: 3295686. DOI: 10.1186/1755-8794-5-5. View

Ito S, Shen L, Dai Q, Wu S, Collins L, Swenberg J . Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011; 333(6047):1300-3. PMC: 3495246. DOI: 10.1126/science.1210597. View

Mederacke I, Hsu C, Troeger J, Huebener P, Mu X, Dapito D . Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013; 4:2823. PMC: 4059406. DOI: 10.1038/ncomms3823. View

Cedar H, Bergman Y . Programming of DNA methylation patterns. Annu Rev Biochem. 2012; 81:97-117. DOI: 10.1146/annurev-biochem-052610-091920. View

10.

Meissner A, Gnirke A, Bell G, Ramsahoye B, Lander E, Jaenisch R . Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res. 2005; 33(18):5868-77. PMC: 1258174. DOI: 10.1093/nar/gki901. View

11.

Rippe R, Brenner D . From quiescence to activation: Gene regulation in hepatic stellate cells. Gastroenterology. 2004; 127(4):1260-2. DOI: 10.1053/j.gastro.2004.08.028. View

12.

Tag C, Sauer-Lehnen S, Weiskirchen S, Borkham-Kamphorst E, Tolba R, Tacke F . Bile duct ligation in mice: induction of inflammatory liver injury and fibrosis by obstructive cholestasis. J Vis Exp. 2015; (96). PMC: 4354634. DOI: 10.3791/52438. View

13.

Yang H, Liu Y, Bai F, Zhang J, Ma S, Liu J . Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene. 2012; 32(5):663-9. PMC: 3897214. DOI: 10.1038/onc.2012.67. View

14.

Henderson N, Arnold T, Katamura Y, Giacomini M, Rodriguez J, McCarty J . Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013; 19(12):1617-24. PMC: 3855865. DOI: 10.1038/nm.3282. View

15.

Mann D . Epigenetics in liver disease. Hepatology. 2014; 60(4):1418-25. PMC: 4258082. DOI: 10.1002/hep.27131. View

16.

Rangnekar A, Lammert F, Igolnikov A, Green R . Quantitative trait loci analysis of mice administered the methionine-choline deficient dietary model of experimental steatohepatitis. Liver Int. 2006; 26(8):1000-5. DOI: 10.1111/j.1478-3231.2006.01314.x. View

17.

Iwaisako K, Jiang C, Zhang M, Cong M, Moore-Morris T, Park T . Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci U S A. 2014; 111(32):E3297-305. PMC: 4136601. DOI: 10.1073/pnas.1400062111. View

18.

de Vries E, Beuers U, Ponsioen C . Biomarkers for disease progression of primary sclerosing cholangitis. Curr Opin Gastroenterol. 2015; 31(3):239-46. DOI: 10.1097/MOG.0000000000000163. View

19.

Nestor C, Ottaviano R, Reddington J, Sproul D, Reinhardt D, Dunican D . Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Res. 2011; 22(3):467-77. PMC: 3290782. DOI: 10.1101/gr.126417.111. View

20.

Murphy S, Yang H, Moylan C, Pang H, Dellinger A, Abdelmalek M . Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology. 2013; 145(5):1076-87. PMC: 3805742. DOI: 10.1053/j.gastro.2013.07.047. View